We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current GNNSF market cap is 3.12B. The company's latest EPS is USD -0.0450 and P/E is -32.67.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 273.35M | 390.85M | 490.1M | 625.7M | 839.53M |
| Operating Income | -123.92M | -196.32M | -371.01M | -447.32M | -401.5M |
| Net Income | -96.91M | -204.95M | -358.71M | -226.85M | -95.48M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 889.41M | 1.45B | 2.23B | 2.55B | 3.39B |
| Total Liabilities | 517.11M | 631.82M | 846.18M | 1.18B | 1.34B |
| Total Equity | 372.3M | 815.59M | 1.39B | 1.36B | 2.04B |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -29.96M | -151.09M | -136.79M | -120.29M | -286.91M |
| Investing | -208.63M | -100.17M | -212.55M | -443.3M | -357.73M |
| Financing | -2.78M | 624.2M | 902.14M | 419.32M | 1.07B |
| Market Cap | 3.12B |
| Price to Earnings Ratio | -32.67 |
| Price to Sales Ratio | 3.72 |
| Price to Cash Ratio | 2.16 |
| Price to Book Ratio | 1.53 |
| Dividend Yield | - |
| Shares Outstanding | 2.12B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 259.71k |
| 52 Week Change | -36.09% |
| 52 Week High | 3.20 |
| 52 Week Low | 1.47 |
| Spread (Intraday) | 0.22 (12.94%) |
| Company Name | Genscript Biotech Corporation (PK) |
| Address |
4th floor, harbour place grand cayman KY1-1002 |
| Website | https://www.genscript.com |
| Industry | coml physical, biologcl resh (8731) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
